CompletedEUCTR 2009-016667-11

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesBipolarity

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Bulgaria · France and 1 more location
Study phase: Phase 3

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 660
Sponsor: Cephalon, Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: France, Bulgaria, Spain
Age range: Not clearly listed
Official registry ID: EUCTR 2009-016667-11
Official title: Show the full official title
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bulgaria · France · Spain

Registry details

Historical country statuses

Bulgaria — Completed
Spain — Completed
France — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Cephalon, Inc.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me